Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Intensive Stroke Cycling for Optimal Recovery and Economic Value Trial: Protocol for a Randomized Clinical Trial.

Physical therapy·2025
Same author

Noninferiority Randomized Clinical Trial Comparing Three Delivery Formats of a Rehabilitation Intervention to Reduce Fatigue Among Individuals With Multiple Sclerosis.

Archives of physical medicine and rehabilitation·2025
Same author

Thalamotomy for tremor performed by Irving S. Cooper.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2025
Same author

Forced-Rate Aerobic Cycling Improves Locomotor Function and Gait Biomechanics in Individuals With Chronic Stroke: A Randomized Controlled Trial.

American journal of physical medicine & rehabilitation·2025
Same author

Characteristics of Ipsilateral Corticomotor Pathways in People with cervical spinal cord Injury.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2025
Same author

Feasibility and Outcomes of Gait Training With a Powered Exoskeleton in Individuals With Multiple Sclerosis.

American journal of physical medicine & rehabilitation·2025
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
13:02

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

Gait disorders in multiple sclerosis.

Francois Bethoux1

  • 1Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk U10, Cleveland, OH 44195, USA. bethouf@ccf.org

Continuum (Minneapolis, Minn.)
|August 7, 2013
PubMed
Summary
This summary is machine-generated.

Mobility and walking are significantly impacted by multiple sclerosis (MS). Early identification and a multimodal management approach are crucial for addressing gait disorders in MS patients.

More Related Videos

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

Using the MouseWalker to Quantify Locomotor Dysfunction in a Mouse Model of Spinal Cord Injury
07:28

Using the MouseWalker to Quantify Locomotor Dysfunction in a Mouse Model of Spinal Cord Injury

Published on: March 24, 2023

Related Experiment Videos

Last Updated: May 9, 2026

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
13:02

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

Using the MouseWalker to Quantify Locomotor Dysfunction in a Mouse Model of Spinal Cord Injury
07:28

Using the MouseWalker to Quantify Locomotor Dysfunction in a Mouse Model of Spinal Cord Injury

Published on: March 24, 2023

Area of Science:

  • Neurology
  • Rehabilitation Medicine
  • Clinical Research

Background:

  • Multiple sclerosis (MS) frequently impairs ambulation and overall mobility.
  • Gait disorders are a significant concern affecting the quality of life for MS patients and their families.

Observation:

  • Recent surveys confirm a high prevalence of walking limitations in MS.
  • Validated outcome measures include the Timed 25-Foot Walk, 6-Minute Walk, and MSWS-12.
  • Gait analysis systems, pedometers, and oscillometers aid in characterizing gait disorders.

Findings:

  • Rehabilitation interventions demonstrate benefits for walking performance in MS.
  • Dalfampridine is the first approved symptomatic medication to improve walking in MS.
  • Emerging assistive devices show promise, while spasticity treatments require further gait enhancement assessment.

Implications:

  • Early identification and management of gait disorders in MS are essential.
  • A multimodal, adaptable treatment strategy is recommended for MS-related mobility issues.
  • Ongoing assessment is key to adjusting management plans for optimal patient outcomes.